News

The Valstar-specific issues that caused the 2002 withdrawal of the product from the market have been reportedly resolved. However, during a recent FDA pre-approval inspection of the company’s

As part of the settlement an undisclosed cash consideration was paid by Ventana to Qiagen and Qiagen acknowledges that pursuant to an asset purchase agreement dated September 23,

Under the revised agreement, Altus regains control of its ALTU-238 assets and Genentech has agreed to provide, for a limited term, supplies of human growth hormone for future

The Ministry of Health and Medical Education (MOHME) will purchase 20,000 vials of Haemate P in 500 IU vials in the first year of launch, administering it in

James Karis, president and CEO of Entelos, said: “The deal reinforces Entelos’s stated strategy to enable proprietary drug development, particularly in chronic disease areas where multiple drugs, treatment

In September, the company reported that the FDA had opened the investigational new drug application (IND) for Corlux for the treatment of endogenous Cushing’s syndrome, which allowed it

The acquisition follows the US Federal Trade Commission’s early termination of the waiting period required by US antitrust law. With the completion of the acquisition, Reliant’s cardiovascular medicines

The acquisition gives GlaxoSmithKline marketing rights to Lovaza in the US and Puerto Rico. In addition to Lovaza, three other cardiovascular products marketed by Reliant – DynaCirc CR

In addition to the initial milestone payment, Elbion would be entitled to additional payments from Wyeth based on the achievement of further milestones. Payments to Elbion under the